LIFEPHARMS, INC.

Basic Information

143 Shaw Street
New London, CT, 06320-

Company Profile

n/a

Additional Details

Field Value
DUNS: 172904067
Hubzone Owned: N
Socially and Economically Disadvantaged: Y
Woman Owned: N
Number of Employees: n/a


  1. Hsp90 inhibitors to combat antifungal drug resistance.

    Amount: $299,998.00

    DESCRIPTION (provided by applicant): Fungal infections continue to be a major cause of morbidity and mortality among HIV-infected patients. Many of the emerging fungal pathogens that are resistant to ...

    SBIR Phase I 2012 Department of Health and Human Services
  2. Novel Antibacterial Scaffold from Natural Products

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Despite the rise of bacterial resistance to antibiotics, the development of new antibiotics is on the decline. Methicillin-resistant Staphococcal aureus infections ...

    SBIR Phase I 2011 Department of Health and Human Services
  3. Novel antifungals for Immunocompromised/HIV patients.

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): Fungal infections continue to be a major cause of morbidity and mortality among HIV- infected patients. At present, there are only three classes of antifungal age ...

    SBIR Phase I 2011 Department of Health and Human Services
  4. Discovery of novel agents against M. tuberculosis.

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): Despite the fact that tuberculosis is a major public global health problem, there have been no drugs developed for it since the 1960s. In 2006 tuberculosis caused ...

    SBIR Phase I 2010 Department of Health and Human Services
  5. Nucleoside hydrolase Inhibitors from natural products for Leishmania

    Amount: $211,698.00

    DESCRIPTION (provided by applicant): Our goal is to identify novel drugs for the treatment and chemoprophylaxis of Leishmania by blocking nucleoside hydrolase (NH) activity of this parasite. Leishmani ...

    SBIR Phase I 2010 Department of Health and Human Services
  6. Discovery of novel antibacterials from a mushroom natural product library

    Amount: $378,012.00

    DESCRIPTION (provided by applicant): The dramatic increase in the prevalence of antibiotic resistance among important hospital- and community-acquired bacterial pathogens poses a serious threat to our ...

    SBIR Phase I 2009 Department of Health and Human Services
  7. Discovery of cell cycle inhibitors from natural products

    Amount: $904,482.00

    DESCRIPTION (provided by applicant): The need for new and effective chemotherapeutic agents that selectively target cancer cells and thus, would have a much higher therapeutic index is urgent. Most c ...

    SBIR Phase II 2005 Department of Health and Human Services
  8. POTENTIAL ANTICANCER AGENTS FROM BASIDIOMYCETES

    Amount: $100,000.00

    LifePharms, Inc. has established a collection of >12,000 unique species of basidiomycetes/ascomycetes, and the Natural Products Laboratory of Research Triangle Institute has a long and successful hist ...

    SBIR Phase I 2001 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government